Xceleron

Xceleron CSO, Dr Graham Lappin, to Present at ASCPT Meeting in March 2012

Lucy — Tue, 21 Feb 2012 20:38:29 +0000

Date Posted:

21st February, 2012

Summary:

At this year’s ASCPT meeting, to be held at the Gaylord National Hotel & Convention Center, National Harbor, Maryland from 12 – 17th March, Xceleron’s CSO, Dr Graham Lappin, will be giving a presentation entitled:

“Analytical Technologies for Metabolite Identification and Quantitation”

The talk will be given as part of a workshop called “Metabolites in Safety Testing: What Have Clinical Pharmacologists MIST” to be given on the morning of Saturday 17th March and will include speakers from the FDA and Pfizer.

The presentation will give an overview on the methods available for the identification and quantitation of metabolites to satisfy the MIST guidance, as well as describing how Accelerator Mass Spectrometry can be used as part of an overall strategy in combination with other technologies to give quantifiable measurement of metabolites in all matrices. Case studies from industry will also be given as examples.

If you cannot attend the Workshop and would like to receive a copy of the presentation after the event, please contact Xceleron by email: info@xceleron.com

Click to see more news

Xceleron Inc Doors Open For Visitors During ASCPT Week

Lucy — Tue, 21 Feb 2012 20:37:28 +0000

Date Posted:

21st February, 2012

Summary:

During the ASCPT meeting to be held at the Gaylord National Hotel & Convention Center National Harbor, Maryland, this year, Xceleron will be opening the doors to it’s purpose built facility in Germantown and arranging transport from the Gaylord National Conference Center to and from the site in Germantown. Travel time is approximately 45 minutes and trips will be arranged for 14th, 15th and 16th March.

Xceleron announced the re-opening of it’s state-of-the-art AMS facility in February this year, along with further investment from it’s investors to augment it’s analytical capability.
If you would like to take the opportunity to visit the facility during the ASCPT conference, please contact us by email: info@xceleron.com and we will contact you to arrange travel details.

Click to see more news

Xceleron Announces New Investment and Move to Purpose-built Laboratories in U.S.

Lucy — Mon, 06 Feb 2012 18:46:43 +0000

Date Posted:	6th February 2012
Summary:	XCELERON, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company’s business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012.

Xceleron is relocating senior analytical staff to Germantown from York, hiring new staff in Maryland and retaining a strong study design and project management presence in the UK. The Germantown facility was opened for business in 2008 and has conducted a range of customer studies including absolute bioavailability, metabolism and general pharmacokinetic investigations. 12,000 samples have been analyzed on site for a growing client base of pharmaceutical and biotech companies.

Xceleron intends to augment its analytical capability in Germantown with the latest in highly sensitive LC-MS/MS technology. This addition will create the first laboratory of its kind in which all forms of microtracer and microdose investigations can be conducted in one custom-built facility.

Stuart Best, Vice President Analytical Operations added: “The combined ruggedness of AMS and the specificity of the most sensitive LC-MS/MS will enable a highly cost-effective and safe bridge from discovery to the clinic.”

Xceleron CEO Michael Butler commented: “Our customers told us that they want access to the best analytical platforms in translational science. We are providing that access with the most experienced team in the business and in one highly efficient and purpose built location. This is a first-of-a-kind combination from Xceleron that we believe will add to our customers’ drive for Phase 2-readiness”

-ends-

About Xceleron:
Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials.

Xceleron pioneered the use of human microtracer and AMS and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland. For company information, visit Xceleron at www.xceleron.com
Click to see more news

Roche Wins Approval for Targeted Cancer Drug Vismodegib

Lucy — Tue, 31 Jan 2012 17:07:59 +0000

Date Posted:

January 31st, 2012

Summary:

Yesterday the FDA announced that Roche and Genentech had been granted approval for the targeted cancer drug, Vismodegib for the treatment of basal cell carcinoma.
The approval was granted under the agency’s priority review program that provides for an expedited six-month review of drugs that may offer major advances in treatment.

Further details can be found on the FDA website: link

To download a poster showing how Xceleron helped Genentech determine the absolute bioavailability and changes in the fundamental pharmacokinetics of Vismodegib using an IV microtracer, please click here: Link

To download a publication describing how scientists at Genentech used AMS to determine routes of elimination and extent of vismodegib metabolism, please click here: Link

For company information, visit Xceleron at www.xceleron.com
Click to see more news

Single and Multiple-Dose IV and Oral Pharmacokinetics of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) During a Phase 1 Study in Healthy Female Subjects

Lucy — Tue, 31 Jan 2012 16:28:13 +0000

Summary: This poster, published at the ASCPT meeting in Dallas, Texas, in 2011, describes how scientists at Genentech used the AMS enabled IV tracer approach to investigate the previously observed non-linear pharmacokinetics (PK) of vismodegib (GDC-0449). By administering a 14C-labelled IV microtracer of Vismodigib in addition to an oral dose, they were able to determine how PK behavior changed with multiple daily dosing relative to a single dose.
Published Date:	March 2-5, 2011
Authors:	R. A. Graham, C.E.C.A. Hop, B. L. Lum, D. Colburn, I. Chang, Y. Shin, V. Malhi, M. Xie, J. A. Low, M. J. Dresser
Download	[contact-form]

Click to see more publications